prof. dr hab. Joanna Mika

prof. dr hab. Joanna Mika

+48 12 6623298
pokój 226
Zakład Farmakologii Bólu

Dokonania naukowe

  • Publikacje
  • Granty

Perioperative Immunosuppression and Risk of Cancer Progression: The Impact of Opioids on Pain Management

Autorzy: Renata Zajączkowska, Wojciech Leppert, Joanna Mika, Magdalena Kocot-Kępska, Jarosław Woroń, Anna Wrzosek, Jerzy Wordliczek

DOI: 10.1155/2018/9293704
Date: 2018-09-19

Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic Pain Model.

Autorzy:

DOI: 10.1016/j.neuroscience.2018.08.013
Date: 2018-09-01

Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies.

Autorzy:

DOI: 10.1016/j.bbadis.2018.07.032
Date: 2018-08-01

Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model.

Autorzy:

DOI: 10.3389/fphar.2018.00724
Date: 2018-07-11

Targeting the NLRP3 Inflammasome-Related Pathways via Tianeptine Treatment-Suppressed Microglia Polarization to the M1 Phenotype in Lipopolysaccharide-Stimulated Cultures

Autorzy: Joanna Ślusarczyk, Ewa Trojan, Katarzyna Głombik, Anna Piotrowska, Bogusława Budziszewska, Marta Kubera, Katarzyna Popiołek-Barczyk, Władysław Lasoń, Joanna Mika, Agnieszka Basta-Kaim

DOI: 10.3390/ijms19071965
Date: 2018-07-05

Antinociceptive effects of novel histamine H3 and H4 receptor antagonists and their influence on morphine analgesia of neuropathic pain in the mouse

Autorzy: Katarzyna Popiolek‐Barczyk, Dorota Łażewska, Gniewomir Latacz, Agnieszka Olejarz, Wioletta Makuch, Holger Stark, Katarzyna Kieć‐Kononowicz, Joanna Mika

DOI: 10.1111/bph.14185
Date: 2018-07-01

Botulinum Toxin Type A-A Modulator of Spinal Neuron-Glia Interactions under Neuropathic Pain Conditions.

Autorzy:

DOI: 10.3390/toxins10040145
Date: 2018-04-02

Involvement of Macrophage Inflammatory Protein-1 Family Members in the Development of Diabetic Neuropathy and Their Contribution to Effectiveness of Morphine.

Autorzy:

DOI: 10.3389/fimmu.2018.00494
Date: 2018-03-12

The importance of chemokines in neuropathic pain development and opioid analgesic potency.

Autorzy:

DOI: 10.1016/j.pharep.2018.01.006
Date: 2018-02-01

Tapentadol - A representative of a new class of MOR-NRI analgesics.

Autorzy:

DOI: 10.1016/j.pharep.2018.01.005
Date: 2018-01-31

Grant

OPUS 22 2021/43/B/NZ7/00230 Nowe strategie w farmakoterapii bólu neuropatycznego oparte na modulacji układu chemokin i jego wpływie na rozwój tolerancji opioidowej

15.07.2022 – 14.07.2026

Zobacz także